GVB Biopharma, a 22nd Century Group company, has opened a new, strategically-located distribution facility in the Netherlands to support its growing business in Europe, the Middle East, and Africa (EMEA).
The new distribution facility will increase existing and new customer access to GVB’s quality hemp and cannabis products, speed up transaction flow, and optimise cross-border tax and customs treatment.
GVB is a global-scale specialty ingredient supplier and contract development & manufacturing organization (CDMO) with manufacturing locations in Nevada and Oregon.
Read more: Cross-party group established for recreational cannabis in Europe
Recent increases in the company’s US manufacturing capacity are complementary to the advent of the company’s Netherlands distribution facility. Additional capacity is in part earmarked to satisfy increasing demand in European markets where margins are higher than in the US.
Chief Executive Officer of 22nd Century Group, James A. Mish, commented: “We are excited to expand our business operations in Europe, allowing our customers and partners to access quality products in a more efficient manner.
“With our new Netherlands distribution facility, we can now deliver product to our partners in half the time and better serve our growing customer base with quality distillate and isolates.
“In Europe, the hemp/cannabis industry is expanding rapidly and is expected to reach €3.2bn by 2025. Our new facility will allow us to capture more of that market share, scale our operations, and expand our customer base in this region.”
The company is currenytly is the largest merchant provider of cannabinoid extracts and isolates in North America with a focus on cannabidiol (CBD) and cannabigerol (CBG) extracted and refined at an industrial scale into distillates and isolates. GVB Biopharma’s facilities are NSF International audited and are cGMP Registered for dietary supplements manufacturing.
